STK-002
STK-002-OA-101
Phase 1 small_molecule active
Quick answer
STK-002 for Autosomal Dominant Optic Atrophy is a Phase 1 program (small_molecule) at Stoke Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Stoke Therapeutics
- Indication
- Autosomal Dominant Optic Atrophy
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active